Artigo: Increased Insulin Requirements During Exercise at Very High Altitude in Type 1 Diabetes
- Pieter de Mol, MD1,2,
- Suzanna T. de Vries, MD3,
- Eelco J.P. de Koning, MD, PHD4,5,
- Rijk O.B. Gans, MD, PHD6,
- Cees J. Tack, MD, PHD2 and
- Henk J.G. Bilo, MD, PHD6,7
+ Author Affiliations
1Department of Internal Medicine, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands
2Department of Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
3Department of Cardiology, Tjongerschans Hospital, Heerenveen, the Netherlands
4Department of Nephrology, Leiden University Medical Centre, Leiden, the Netherlands
5Department of Endocrinology, Leiden University Medical Centre, Leiden, the Netherlands
6Department of Internal Medicine, University Medical Centre, Groningen, the Netherlands
7Department of Internal Medicine, Isala Clinics, Zwolle, the Netherlands
- Corresponding author: Pieter de Mol, firstname.lastname@example.org.
OBJECTIVE Safe, very high altitude trekking in subjects with type 1 diabetes requires understanding of glucose regulation at high altitude. We investigated insulin requirements, energy expenditure, and glucose levels at very high altitude in relation to acute mountain sickness (AMS) symptoms in individuals with type 1 diabetes.
RESEARCH DESIGN AND METHODS Eight individuals with complication-free type 1 diabetes took part in a 14-day expedition to Mount Meru (4,562 m) and Mount Kilimanjaro (5,895 m) in Tanzania. Daily insulin doses, glucose levels, energy expenditure, and AMS symptoms were determined. Also, energy expenditure and AMS symptoms were compared with a healthy control group.
RESULTS We found a positive relation between AMS symptoms and insulin requirements (r = 0.78; P = 0.041) and AMS symptoms and glucose levels (r = 0.86; P = 0.014) for Mount Kilimanjaro. Compared with sea level, insulin doses tended to decrease by 14.2% (19.7) (median [interquartile range]) (P = 0.41), whereas glucose levels remained stable up to 5,000 m altitude. However, at altitudes >5,000 m, insulin dose was unchanged (36.8 ± 17 vs. 37.6 ± 19.1 international units [mean ± SD] P = 0.75), but glucose levels (7.5 ± 0.6 vs. 9.5 ± 0.8 mmol/L [mean ± SD] P = 0.067) and AMS scores (1.3 ± 1.6 vs. 4.4 ± 4 points [mean ± SD] P = 0.091) tended to increase. Energy expenditure and AMS symptoms were comparable in both groups (P = 0.84).
CONCLUSIONS Our data indicate that in complication-free individuals with type 1 diabetes, insulin requirements tend to increase during altitudes above 5,000 m despite high energy expenditure. This change may be explained, at least partly, by AMS.
- Received October 25, 2010.
- Accepted December 21, 2010.
© 2011 by the American Diabetes Association.
Link para a matéria completa: http://care.diabetesjournals.org/content/34/3/591.abstract